FDA Approves Nasal Spray for Allergic Reactions
Needle-Free Alternative to EpiPen
August 11, 2024
The Food and Drug Administration (FDA) has approved a nasal spray as the first needle-free treatment for potentially fatal allergic reactions. The spray, called neffy, is intended as an alternative to EpiPen and other autoinjectors.
The FDA approved neffy on Friday, August 9, 2024. The spray is indicated for the emergency treatment of anaphylaxis, a severe allergic reaction that can be life-threatening. Anaphylaxis can be caused by a variety of allergens, including food, medications, and insect stings.
Neffy is a single-use nasal spray that delivers a dose of epinephrine, the same medication that is found in EpiPen. Epinephrine works by constricting blood vessels and relaxing the muscles in the airways, which helps to relieve symptoms of anaphylaxis such as difficulty breathing, swelling, and hives.
Neffy is the first non-injected treatment for anaphylaxis. It is a safe and effective alternative to EpiPen for people who are allergic to needles or who have difficulty using autoinjectors.
Comments